To evaluate follow-up after α-interferon (IFN) discontinuation, 23 patients with chronic myeloid leukemia (CML) in stable complete molecular response (CMolR) with IFN were revisited. After a median IFN treatment of 105.8 months (IR 56.1 - 127.3), all patients discontinued IFN for prolonged CMolR (12), intolerance (8) or planned ABMT (3). After 12.5 months, one patient developed an extramedullar blast crisis. Four patients needed to start imatinib, all achieving again molecular response. Eighteen patients are still off-therapy (median time from IFN discontinuation 125.5 months, IR 86.9-205.3); among these, five are BCR-ABL negative, six present with a sporadic positivity (BCR-ABL ratio < 0.1) and seven show a stable and long-lasting mild positivity (BCR-ABL ratio < 0.5). Patients in prolonged CMolR with IFN have low risk of recurrence after discontinuation; the reappearance of a BCR-ABL positivity < 0.5 did not always precede a relapse, suggesting mechanisms of immunological control induced by IFN.

Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response / Latagliata, R.; Romano, A.; Mancini, M.; Breccia, Massimo; Carmosino, I.; Vozella, F.; Montagna, C.; Volpicelli, P.; De Angelis, F.; Petrucci, L.; Serrao, A.; Molica, M.; Salaroli, A.; Diverio, D.; Alimena, G.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 57:1(2016), pp. 1-17. [10.3109/10428194.2015.1043548]

Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response

Latagliata R.
;
Breccia Massimo;Carmosino I.;Vozella F.;Volpicelli P.;Petrucci L.;Molica M.;Salaroli A.;Alimena G.
2016

Abstract

To evaluate follow-up after α-interferon (IFN) discontinuation, 23 patients with chronic myeloid leukemia (CML) in stable complete molecular response (CMolR) with IFN were revisited. After a median IFN treatment of 105.8 months (IR 56.1 - 127.3), all patients discontinued IFN for prolonged CMolR (12), intolerance (8) or planned ABMT (3). After 12.5 months, one patient developed an extramedullar blast crisis. Four patients needed to start imatinib, all achieving again molecular response. Eighteen patients are still off-therapy (median time from IFN discontinuation 125.5 months, IR 86.9-205.3); among these, five are BCR-ABL negative, six present with a sporadic positivity (BCR-ABL ratio < 0.1) and seven show a stable and long-lasting mild positivity (BCR-ABL ratio < 0.5). Patients in prolonged CMolR with IFN have low risk of recurrence after discontinuation; the reappearance of a BCR-ABL positivity < 0.5 did not always precede a relapse, suggesting mechanisms of immunological control induced by IFN.
2016
chronic myeloid leukemia; treatment discontinuation; α-interferon; adult; antineoplastic agents; biomarkers; combined modality therapy; female; hematopoietic stem cell transplantation; humans; interferon-alpha; leukemia; myelogenous; chronic; bcr-abl positive; male; middle aged; remission induction; treatment outcome
01 Pubblicazione su rivista::01a Articolo in rivista
Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response / Latagliata, R.; Romano, A.; Mancini, M.; Breccia, Massimo; Carmosino, I.; Vozella, F.; Montagna, C.; Volpicelli, P.; De Angelis, F.; Petrucci, L.; Serrao, A.; Molica, M.; Salaroli, A.; Diverio, D.; Alimena, G.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 57:1(2016), pp. 1-17. [10.3109/10428194.2015.1043548]
File allegati a questo prodotto
File Dimensione Formato  
Latagliata_Discontinuation_2016.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.62 MB
Formato Adobe PDF
1.62 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1466284
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 10
social impact